Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $54 from $74 and keeps a Buy rating on the shares. The target reduction comes following its update from its ongoing Ph3 studies. The main takeaway is that things are *mostly* on track. Newly updated / slightly delayed is progress with the MAGNITUDE study of nex-z for ATTR-CM – the company has enrolled about 48% of the target number of patients so far though now plans to complete enrollment by early 2027 versus YE26 previously.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
- Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
- Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
- Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
- Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today